The 12th Annual two-day WIN Symposium 2022, co-chaired by Richard L. Schilsky and our Director, Josep Tabernero, Chairman and Vice-Chairman…
en_news
The “J-BID – José Baselga Innovative Disruption Program” has an investment of up to 6 million euros and aims to…
HER2DX is the world’s first diagnostic test formulated specifically for HER2-positive (HER2+) breast cancer. HER2DX analyzes RNA on 27 genes…
In her latest ESMO perspectives On target column entitled Food for thought: dietary effects on tumor metabolism & progression, VHIO’s Elena Garralda, Principal…
Co-chaired by VHIO’s Director, Josep Tabernero, and Richard L. Schilsky, Chairman of the WIN Consortium, the 12th annual WIN Symposium…
1 September 2021, Utrecht (The Netherlands) – A new international consortium of academic and industrial leaders in the field of cancer…
PARP inhibitors (PARPi) are approved for treating advanced prostate cancers with various defective DNA repair genes, although not all patients…
Barcelona, August 25, 2021. Multiple myeloma (MM), although relatively rare, is a highly heterogeneous cancer accounting for around 10% of…
Barcelona, August 24, 2021. Launched back in 2016 by Spanish Association against Cancer (AECC), and organized in collaboration with the…
Barcelona, August 02, 2021. The BRCA1 and BRCA2 genes are crucial actors in the DNA damage response and repair pathway;…
